Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.
Elinzanetant 治療與更年期相關的血管運動症狀:OASIS 1 和 2 隨機臨床試驗。
JAMA 2024-08-22
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
SONAR試驗事後分析顯示,內皮素受體拮抗劑atrasentan與2型糖尿病和慢性腎臟疾病患者的疼痛減少有關。
Kidney Int 2023-11-22
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Zibotentan與dapagliflozin組合藥物與單獨dapagliflozin在慢性腎臟病患者中的比較(ZENITH-CKD):一項多中心、隨機、主動對照、2b期臨床試驗。
Lancet 2023-12-12
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
KarXT(xanomeline-trospium)在美國精神分裂症中的功效和安全性(EMERGENT-2):來自一項隨機、雙盲、安慰劑對照、靈活劑量的第3期試驗的結果。
Lancet 2024-01-15
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
慢性腎臟病的醛固酮合成酶抑制及是否搭配 empagliflozin 的療效和安全性:一項隨機、對照的2期試驗。
Lancet 2024-02-01
Zibotentan Can Be Co-administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug-Drug Interaction Study.
Zibotentan可與含有乙炔雌二醇和左炔诺孕酮的避孕藥同時使用:藥物動力學藥物相互作用研究。
Clin Pharmacol Ther 2024-04-30